viral
infect
major
caus
morbid
mortal
elderli
peopl
young
children
throughout
world
common
pathogen
includ
coxsacki
viru
cv
respiratori
syncyti
viru
rsv
howev
antivir
agent
low
toxic
drug
resist
current
avail
clinic
therapi
present
studi
aim
examin
antivir
activ
emodin
ingredi
rheum
palmatum
cvb
rsv
infect
attempt
discov
new
antivir
agent
viru
infect
monom
emodin
extract
isol
rheum
palmatum
antivir
activ
emodin
cell
evalu
includ
viru
replic
inhibit
virucid
antiabsorpt
effect
bromid
mtt
assay
plaqu
reduct
assay
pra
kinet
viru
inhibit
emodin
period
h
determin
plaqu
assay
quantit
real
time
pcr
qpcr
cytokin
mrna
express
emodin
treatment
also
assess
qpcr
postinfect
result
show
emodin
potent
inhibitori
activ
cvb
rsv
effect
concentr
ec
rang
select
index
si
howev
emodin
could
nt
directli
inactiv
virus
block
absorpt
cell
act
biolog
synthesi
inhibitor
cvb
rsv
concentrationand
timedepend
manner
especi
first
h
postinfect
moreov
emodin
could
decreas
mrna
express
enhanc
express
significantli
compar
viral
control
vitro
result
provid
molecular
basi
develop
emodin
novel
safe
antivir
agent
human
enteroviru
respiratori
viru
infect
clinic
therapi
coxsackieviru
group
b
cvb
infect
character
asymptomat
infect
undifferenti
febril
ill
mild
upper
respiratori
symptom
occasion
cvb
caus
inflammatori
diseas
pancrea
heart
central
nervou
system
coxsackieviru
b
cvb
belong
picornavirida
famili
one
six
serotyp
cvb
among
top
five
commonli
identifi
enteroviru
ev
type
exhibit
highest
annual
preval
countri
associ
enceph
myocard
immunocompromis
children
central
nervou
system
cn
diseas
older
adult
typic
clinic
outbreak
cvb
result
acut
mening
recent
cvb
report
respons
outbreak
neurolog
hand
foot
mouth
diseas
china
human
respiratori
syncyti
viru
rsv
member
paramyxovirida
famili
common
widespread
respiratori
tract
infecti
agent
result
approxim
million
infect
death
year
import
caus
lower
respiratori
zhao
liu
email
mailscueceducn
correspond
author
project
support
grant
nation
mega
project
major
drug
develop
nation
natur
scienc
foundat
china
tract
lrt
infect
bronchiol
pneumonia
young
children
neonat
give
rise
acut
lrt
associ
death
young
children
develop
countri
clinic
sever
rsv
infect
primarili
seen
young
children
immun
system
andor
genet
predisposit
patient
suppress
tcell
immun
elderli
control
rna
viru
includ
cvb
rsv
infect
relat
diseas
remain
public
health
concern
evspecif
vaccin
licens
rsv
vaccin
avail
clinic
use
efficaci
therapeut
reagent
cvb
rsv
infect
woefulli
unsatisfactori
ribavirin
licens
treatment
viru
infect
limit
efficaci
caus
side
effect
hemolyt
anemia
ineffect
ribavirin
antivir
due
virusinduc
inflammatori
respons
gener
infect
persist
viru
replic
end
tradit
chines
medicin
tcm
well
known
clinic
research
abund
resourc
low
toxic
high
effici
therefor
screen
antivir
agent
compound
chines
herbal
medicin
benefici
emodin
anthraquinon
deriv
root
rheum
palmatum
report
emodin
possess
number
biolog
activ
oxidas
inhibit
antiinflammatori
antivir
vasorelax
immunosuppress
hepatoprotect
antitumor
effect
evalu
antivir
activ
action
mechan
emodin
cellular
event
viral
life
cycl
investig
emodin
effect
two
human
pathogen
rna
virus
cvb
rsv
tissu
cultur
cell
studi
human
laryng
carcinoma
cell
routin
grown
dulbecco
modifi
eagl
medium
dmem
supplement
fetal
calf
serum
gibco
usa
penicillin
uml
streptomycin
lglutamin
medium
use
cytotox
antivir
assay
contain
serum
cvb
strain
maintain
laboratori
propag
cell
rsv
kindli
provid
professor
paton
depart
children
health
glasgow
univers
england
cvb
rsv
prolifer
cell
harvest
typic
cytopath
effect
cpe
could
observ
cell
rheum
palmatum
cultiv
collect
high
mountain
area
qinghai
provinc
china
materi
extract
purifi
depart
plant
chemistri
hubei
colleg
tradit
chines
medicin
china
extract
scheme
shown
fig
emodin
one
monom
chloroform
extract
rheum
palmatum
extract
isol
fig
content
emodin
g
rheum
palmatum
mg
term
dri
start
materi
puriti
found
three
independ
experi
ribavirin
purchas
tianjin
pharmaceut
co
ltd
china
viru
titrat
perform
microtitr
plate
dilut
sampl
limit
dilut
method
viru
titer
estim
cytopathogen
cell
induc
viral
infect
express
tissu
cultur
infecti
dose
per
millilit
tcid
ml
reedmuench
method
tcid
ml
cvb
tcid
ml
rsv
quantit
colorimetr
mtt
tetrazolium
bromid
assay
perform
describ
previous
briefli
ml
cell
seed
plate
cultur
atmospher
co
incub
h
subconflu
remov
growth
medium
twofold
serial
dilut
emodin
ribavirin
ad
incub
h
cultur
medium
remov
thiazolyl
blue
tetrazolium
bromid
solut
sigmaaldrich
usa
ad
incub
h
purpl
precipit
fulli
visibl
formazan
dissolv
dimethyl
sulfoxid
dmso
quantit
convent
micropl
reader
nm
accord
manufactur
protocol
toxic
dose
cell
death
cc
calcul
doserespons
curv
basi
absorb
cell
viabil
treat
cell
untreat
cell
data
present
result
experi
perform
triplic
monolay
subconflu
cell
challeng
tcid
cvb
rsv
h
h
incub
viru
adsorpt
cell
wash
twice
pb
incub
test
medium
contain
twofold
serial
dilut
emodin
ribavirin
antivir
activ
dilut
measur
mtt
assay
plaqu
reduct
assay
incub
cvb
incub
rsv
effect
dose
reduct
viral
replic
ed
determin
percentag
inhibit
calcul
follow
mtt
viru
inhibit
rate
test
viru
cell
viru
pra
viru
inhibit
rate
number
plaqu
viru
number
plaqu
test
number
plaqu
viru
select
index
si
evalu
follow
formula
sitd
ed
viral
suspens
contain
tcid
ml
cvb
rsv
either
incub
equal
volum
medium
contain
twofold
serial
dilut
emodin
drugfre
vehicl
h
respect
mixtur
contain
viru
ad
monolay
subconflu
cell
cvb
rsv
co
atmospher
adsorpt
mix
suspens
remov
cell
monolay
rins
care
phosphat
buffer
solut
pb
maintain
test
medium
day
virucid
effect
determin
mtt
assay
follow
procedur
describ
confluent
monolay
cell
preincub
test
media
presenc
absenc
twofold
serial
dilut
emodin
co
atmospher
h
cell
sheet
wash
pb
twice
challeng
tcid
ml
cvb
rsv
h
incub
viru
adsorpt
cell
rins
twice
pb
overlaid
dmem
day
typic
cpe
visibl
inhibit
viru
evalu
mtt
assay
describ
antivir
activ
emodin
also
evalu
plaqu
reduct
assay
pra
briefli
confluent
cell
grown
cultur
plate
infect
cvb
rsv
h
h
adsorpt
cell
wash
twice
prewarm
pb
overlaid
agaros
contain
complet
dmem
differ
dilut
emodin
incub
day
cell
fix
formaldehyd
min
stain
crystal
violet
solut
number
plaqu
count
visual
examin
percentag
plaqu
inhibit
rate
calcul
follow
pra
viru
inhibit
rate
number
plaqu
viru
number
plaque
test
number
plaqu
viru
time
addit
assay
perform
describ
elsewher
briefli
confluent
monolay
cell
cultur
plate
first
infect
tcid
ml
cvb
rsv
h
unbound
viru
rins
monolay
pb
three
time
emodin
dmem
without
serum
ad
well
concurr
viru
infect
h
interv
h
infect
infect
cell
scrape
h
virus
releas
cell
freez
thaw
three
time
cell
debri
remov
centrifug
viru
titer
supernat
determin
plaqueform
assay
percentag
inhibit
calcul
accord
follow
formula
plaqu
format
rate
number
plaqu
form
treat
group
number
plaqu
form
viru
control
total
rna
isol
use
trizol
reagent
list
tabl
pcr
product
resolv
agaros
gel
purifi
accord
instruct
dna
gel
extract
kit
sequenc
confirm
purpos
gene
viru
cvb
rsv
gene
housekeep
gene
gapdh
serial
dilut
obtain
standard
seri
copi
per
ml
step
differ
fold
reaction
perform
biorad
instrument
use
sybr
green
realtim
pcr
master
mix
reagent
toyobo
japan
realtim
pcr
reaction
perform
initi
denatur
min
threestep
cycl
procedur
denatur
anneal
extens
cycl
follow
correspond
standard
seri
obtain
sampl
assay
cvb
rsv
gapdh
thu
copi
number
sampl
emodin
differ
time
could
determin
read
standard
seri
ct
valu
sampl
cytokin
mrna
level
cultur
cell
measur
confluent
monolay
cell
plate
infect
cvb
rsv
incub
h
wash
pb
emodin
ribavirin
ad
co
atmospher
h
viru
ad
sampl
volum
dmem
use
virusinfect
control
cytokin
level
supernat
measur
rel
quantif
mrna
briefli
total
rna
cell
extract
trizol
reagent
revers
transcript
cdna
describ
primer
housekeep
gene
gapdh
shown
tabl
initi
denatur
step
min
threestep
cycl
procedur
carri
cycl
rel
express
level
target
gene
normal
housekeep
gene
gapdh
calcul
use
follow
formula
sampl
perform
least
duplic
sequenc
cvb
forward
revers
rsv
forward
revers
forward
revers
forward
revers
gapdh
forward
revers
set
experi
repeat
least
three
time
consist
result
data
tcid
cc
ec
calcul
analyz
spss
softwar
spss
inc
usa
data
differentdos
treatment
data
cytokin
level
compar
analyz
oneway
analysi
varianc
oneway
anova
lsd
method
p
valu
consid
statist
signific
cytotoxicit
emodin
rheum
palmatum
cell
evalu
mtt
assay
shown
fig
cell
viabil
reduc
increas
drug
concentr
estim
cc
valu
emodin
ribavirin
cell
respect
emodin
caus
visibl
chang
cell
morpholog
cell
densiti
set
highest
nontox
concentr
antivir
assay
cell
treat
emodin
higher
grew
tardili
show
alter
cell
morpholog
antivir
potenti
emodin
cvb
rsv
assess
mtt
assay
pra
use
cell
virusinduc
cpe
normal
appar
day
cvb
day
rsv
postinfect
dramat
delay
emodin
concentrationdepend
manner
shown
fig
note
increas
antivir
effect
observ
increas
drug
concentr
emodin
could
suppress
cvb
rsv
replic
cell
good
concentrationdepend
linear
relationship
p
rsv
p
cvb
also
observ
emodin
viru
inhibitori
rate
result
drug
toxic
show
emodin
act
potent
inhibitor
cvb
rsv
averag
ec
valu
rang
si
ad
postinfect
tabl
ec
si
emodin
show
signific
differ
posit
control
ribavirin
p
indic
anticvb
antirsv
activ
emodin
similar
ribavirin
test
emodin
antivir
adsorpt
directli
inactiv
effect
cvb
rsv
virion
differ
dose
emodin
preincub
cell
incub
viru
h
titrat
residu
infect
determin
plaqu
assay
howev
obviou
antivir
adsorpt
virucid
effect
could
observ
inhibitori
rate
dosag
data
shown
signific
differ
emodintr
group
viru
control
group
preincub
direct
inactiv
assay
p
describ
emodin
treatment
caus
dosedepend
reduct
cvb
rsv
cell
determin
whether
inhibit
viru
replic
emodin
timedepend
compound
ad
indic
time
h
postinfect
growth
cvb
rsv
cell
measur
time
plaqu
assay
qpcr
plaqu
form
fig
h
much
less
h
viru
control
p
plaqu
form
emodin
treat
group
h
significantli
differ
viru
control
group
p
result
suggest
emodin
inhibit
virusspecif
event
within
first
h
cvb
rsv
infect
infecti
viral
particl
supernat
also
quantit
quantit
real
time
pcr
h
postinfect
found
emodin
significantli
inhibit
cvb
emodin
anthraquinon
compound
consist
three
cyclic
ring
activ
constitu
deriv
root
rheum
palmatum
emodin
possess
antibacteri
diuret
vasorelax
antiinflammatori
antiprolif
anticarcinogen
properti
sever
studi
demonstr
effect
emodin
yield
herp
simplex
viru
hepat
b
viru
sever
acut
respiratori
syndrom
sar
coronaviru
etc
emodin
suspect
exhibit
antivir
activ
inhibit
casein
kinas
essenti
phosphoryl
protein
viru
life
cycl
disrupt
lipid
bilay
inactiv
envelop
viru
antivir
activ
emodin
virus
investig
studi
examin
viru
replic
inhibit
virucid
antiabsorpt
effect
cell
mtt
pra
method
emodin
found
present
potent
antivir
activ
ad
infect
ec
si
cvb
ec
si
rsv
respect
emodin
caus
dosedepend
reduct
cvb
rsv
cell
antivir
activ
ribavirin
cvb
rsv
almost
equival
howev
emodin
could
prevent
cell
viru
infect
antiabsorpt
assay
could
show
virucid
effect
cvb
rsv
result
impli
emodin
may
inhibit
viru
biolog
synthesi
rather
directli
inactiv
virus
block
absorpt
suscept
cell
vitro
gain
insight
mechan
emodin
interrupt
viru
replic
time
addit
assay
perform
determin
time
point
maximum
inhibit
emodin
plaqu
form
emodin
ad
immedi
h
viru
adsorpt
rapidli
increas
ad
h
postinfect
qpcr
studi
dramat
reduct
infecti
viru
copi
observ
h
postinfect
coincid
result
plaqu
form
data
demonstr
emodin
may
interrupt
earli
stage
viral
replic
cycl
cytokin
secret
human
bodi
cell
play
critic
role
connect
innat
immun
specif
immun
bodi
demonstr
augment
weaken
host
resist
viru
infect
exampl
specif
express
could
control
hepat
b
viru
replic
vitro
necessari
suffici
clear
measl
viru
infect
brain
tissu
furthermor
could
restrict
celltocel
spread
cvb
heart
limit
myocardi
organ
injuri
observ
protect
pancreat
cell
invad
cvb
activ
resid
macrophag
tnf
polypeptid
cytokin
produc
activ
macrophag
monocyt
cell
prove
pivot
trigger
inflammatori
infect
instanc
overexpress
activ
cardiomyocytespecif
promot
region
also
enhanc
express
varieti
adhes
molecul
requir
inflammatori
cell
infiltr
infect
site
cvb
induc
myocard
investig
effect
emodin
mrna
express
cytokin
reveal
emodin
significantli
increas
mrna
express
decreas
mrna
express
demonstr
emodin
may
strengthen
host
resist
viru
infect
enhanc
express
prevent
viru
induc
inflammatori
respons
inhibit
mrna
express
summari
result
provid
molecular
basi
develop
emodin
novel
safe
antivir
agent
human
enteroviru
respiratori
viru
infect
clinic
therapi
emodin
could
inhibit
replic
cvb
rsv
postinfect
concentrationand
timedepend
manner
possess
antivir
activ
viru
regul
cytokin
express
activ
inflammatori
cytokin
viru
replic
share
intercellular
pathway
find
might
provid
clue
understand
mechan
emodin
act
cascad
emodin
may
antivir
candid
broad
spectrum
antivir
activ
target
interrupt
virus
viru
synthesisrel
protein
earli
stage
viral
replic
cycl
modulatori
function
virusinduc
inflammatori
cytokin
might
contribut
immunoregul
effect
drug
studi
pathway
use
microarray
analysi
western
blot
analysi
need
main
compon
extract
rheum
palmatum
emodin
hold
promis
becom
potenti
therapeut
agent
viru
infect
